Fresh analysis indicates that people who come off blockbuster slimming jabs like semaglutide or tirzepatide may regain shed pounds far faster than those who end conventional diet and exercise regimens.
Published data in a major health publication demonstrates that while obese people frequently drop about a fifth of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"Individuals buying such medications need to be aware of the potential of quick rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain means a return to original weight in about a year and a half.
Analyzing Approaches
The research, which looked at dozens of trials involving over 9,000 of patients, compared the effects of GLP-1 agonists with older methods.
Researchers point out that people who lose weight through diet and exercise generally experience a slower weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Nutrition scientists propose the way of the drugs explains the amplified rebound.
These medications copy a natural hormone called GLP-1, which moderates hunger.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating far more likely."
An Ongoing Issue?
The NHS recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals say that, due to the high risk of relapse, the therapy might need to be long-term.
This opinion is reinforced by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," akin to managing diseases like diabetes.
Patient Experiences
Individuals who have discontinued the jabs describe a intense resurgence of appetite.
"It felt as if a switch that goes on and you're instantly starving," recalled an individual.
The struggle is exacerbated if patients have not developed permanent dietary or behavioural changes during treatment.
Significant Interest
Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is higher among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians stress that while the jabs are potent tools for weight loss, they are not a permanent cure and lasting health benefits likely depends on ongoing lifestyle management.
